Sample Report

Pharma R&D Services Market Report 1st Edition

This report provides a comprehensive overview of the global Pharma R&D Services market from 2024 to 2029. The market is defined as revenue generated from outsourced research and development services commissioned by pharmaceutical companies, including discovery, preclinical, clinical, quality control, diagnostics (CDx/Dx), and bioinformatics services. The landscape is highly dynamic, with market concentration varying by application: select vendors dominate clinical trial services, while the innovation-driven nature of discovery creates a more fragmented and open field. Leading vendors increasingly offer multi-service solutions and flexible service models (e.g., full-service, functional service, or hybrid), often forming strategic partnerships to expand capabilities, accelerate innovation, and enhance integration across the R&D value chain.

This inaugural DeciBio Pharma R&D Services Report is informed by extensive primary research (35 in-depth interviews with pharmaceutical stakeholders and CROs), robust secondary research, proprietary DeciBio tools and datasets, and years of consulting experience in precision medicine. The report delivers both qualitative and quantitative insights across key application areas.

See more details below.

 

 

Complete this form to receive a copy of the sample report.

Report Scope:

Technologies and Revenues Included:
  • Pharma R&D outsourced services – including discovery, preclinical, clinical trial, quality control, diagnostic / companion diagnostic, and bioinformatic (including SaaS) services that pharma accesses via third party vendors
  • Analytical services that are designed to support aspects of discovery, preclinical, clinical, and quality control activities – including genomics, epigenomics, proteomics, cellomics, transcriptomic, microscopy, spectroscopy, chemical analysis (basic analytes), and imaging techniques
  • Revenues associated with contract research organizations, laboratory services providers, and bioinformatic companies to drive drug development 
Technologies and Revenues Excluded:
  • Pharma outsourcing activities related to manufacturing, supply chain logistics and management, regulatory affairs, market access and commercialization, pharmacovigilance, sales trainings, intellectual property consulting, and life cycle management 
  • Service revenues focused on Contract Development and Manufacturing Organizations (CDMOs) or consulting agencies to assist in non-research / trial aspects of drug development
  • Non-R&D specific and non-SaaS informatics solutions leveraged by pharma (e.g., ERP, cloud servers, etc.)
  • Tangential activities to drug development, including environmental monitoring services and direct-to-consumer genetic testing services 

Segmentations Covered in Market Analysis:

Application:
  • Drug Discovery & Design
  • Preclinical Services
  • Clinical Trial Services
  • Quality Control
  • CDx / Dx Development
  • Bioinformatic Technologies
Pharma Type:
  • Large
  • Medium
  • Small
Therapeutic Indication:
  • Oncology
  • Rare Disease
  • Neurology
  • Immunology
  • Cardiology
  • Metabolic
  • Other
Therapeutic Modality:
  • Small Molecule
  • Protein-Based
  • Cell Therapy
  • Gene Therapy
  • Vaccine
  • Other
Company / Provider Type:
  • Specialized CRO
  • General CRO
  • Laboratory Services Provider
  • CDx / Dx Developer
  • Bioinformatics Company
Geography:
  • United States
  • Europe
  • Asia Pacific (APAC)
  • Rest of World (ROW)